1. Home
  2. KPTI vs IHD Comparison

KPTI vs IHD Comparison

Compare KPTI & IHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • IHD
  • Stock Information
  • Founded
  • KPTI 2008
  • IHD 2011
  • Country
  • KPTI United States
  • IHD United States
  • Employees
  • KPTI N/A
  • IHD N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • IHD Investment Managers
  • Sector
  • KPTI Health Care
  • IHD Finance
  • Exchange
  • KPTI Nasdaq
  • IHD Nasdaq
  • Market Cap
  • KPTI 81.1M
  • IHD 89.7M
  • IPO Year
  • KPTI 2013
  • IHD N/A
  • Fundamental
  • Price
  • KPTI $0.63
  • IHD $5.20
  • Analyst Decision
  • KPTI Strong Buy
  • IHD
  • Analyst Count
  • KPTI 4
  • IHD 0
  • Target Price
  • KPTI $5.00
  • IHD N/A
  • AVG Volume (30 Days)
  • KPTI 694.6K
  • IHD 27.7K
  • Earning Date
  • KPTI 02-27-2025
  • IHD 01-01-0001
  • Dividend Yield
  • KPTI N/A
  • IHD 10.32%
  • EPS Growth
  • KPTI N/A
  • IHD N/A
  • EPS
  • KPTI N/A
  • IHD N/A
  • Revenue
  • KPTI $148,442,000.00
  • IHD N/A
  • Revenue This Year
  • KPTI $5.47
  • IHD N/A
  • Revenue Next Year
  • KPTI $6.33
  • IHD N/A
  • P/E Ratio
  • KPTI N/A
  • IHD N/A
  • Revenue Growth
  • KPTI 1.77
  • IHD N/A
  • 52 Week Low
  • KPTI $0.58
  • IHD $4.49
  • 52 Week High
  • KPTI $1.70
  • IHD $5.47
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 46.51
  • IHD 55.82
  • Support Level
  • KPTI $0.60
  • IHD $5.11
  • Resistance Level
  • KPTI $0.70
  • IHD $5.25
  • Average True Range (ATR)
  • KPTI 0.05
  • IHD 0.06
  • MACD
  • KPTI -0.00
  • IHD 0.01
  • Stochastic Oscillator
  • KPTI 46.61
  • IHD 73.68

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About IHD Voya Emerging Markets High Income Dividend Equity Fund

Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.

Share on Social Networks: